Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Voiding Dysfunction in Multiple Sclerosis.
Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
The Correlation between the Virus- and Brain Antigen-Specific B Cell Response in the Blood of Patients with Multiple Sclerosis.
CHMP determines dimethyl fumarate in TECFIDERA® to be a new active substance in the European Union
Neurotrophic and Neuroprotective effects of muscle contraction.
Immunology of Multiple Sclerosis.
Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b.
Some recent advances in multiple sclerosis.
β-Amyloid: Enemy or Remedy?
Drugs@FDA
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Dimethyl fumarate protects pancreatic islet cells and non-endocrine tissue in L-arginine-induced chronic pancreatitis.
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.
A gender gap in autoimmunity.
Teriflunomide in multiple sclerosis: Added benefit not proven
Development of a Bilingual MS-Specific Health Classification System: The Preference-Based Multiple Sclerosis Index.
Neurorehabilitation Topics in Patients with Multiple Sclerosis: From Outcome Measurements to Rehabilitation Interventions.
Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient.
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx
How integrated are neurology and palliative care services? Results of a multicentre mapping exercise.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Rebound Relapses After Ceasing Another Disease-Modifying Treatment in Patients With Multiple Sclerosis: Are There Lessons to Be Learned?
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.

Pages